logo
  

Tupperware Brands Says Tracking Towards High-end Of Local Currency Q3 Sales View

Tupperware Brands Corp. (TUP) said that it is tracking towards the high-end of 4% to 6% growth in local currency sales outlook range for the third quarter.

The company said it has seen the expected trend improvement in Indonesia, France and Italy, and strong growth in its businesses in Argentina, Brazil, China and Tupperware Mexico and South Africa in spite of the macros, which reflects the strength of its business model and skill of its local leadership.

Based on actual foreign exchange rates for July and August rates thereafter, the third quarter impact of changes in foreign exchange rates on the Company's 2015 earnings per share comparison with 2014 would be negative 26 cents per share. There was a negative 22 cent impact included in the guidance provided in July in the Company's second quarter 2015 earnings release.

The Company noted that it plans to release its third quarter 2015 earnings results on October 20, 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT